Signal Genetics (NASDAQ: MGEN) and Cannabis Science (OTCMKTS:CBIS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, analyst recommendations and earnings.
This is a breakdown of current ratings for Signal Genetics and Cannabis Science, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Valuation and Earnings
This table compares Signal Genetics and Cannabis Science’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Signal Genetics||$3.34 million||47.29||-$12.67 million||($8.93)||-0.79|
Cannabis Science has higher revenue, but lower earnings than Signal Genetics. Cannabis Science is trading at a lower price-to-earnings ratio than Signal Genetics, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Signal Genetics has a beta of 1.93, meaning that its stock price is 93% more volatile than the S&P 500. Comparatively, Cannabis Science has a beta of -4.04, meaning that its stock price is 504% less volatile than the S&P 500.
Insider & Institutional Ownership
21.3% of Signal Genetics shares are owned by institutional investors. 44.4% of Signal Genetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This table compares Signal Genetics and Cannabis Science’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Signal Genetics beats Cannabis Science on 8 of the 10 factors compared between the two stocks.
Signal Genetics Company Profile
Signal Genetics, Inc. is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test. The MyPRS test is a microarray-based gene expression profile (GEP), assay that measures the expression level of specific genes and groups of genes that are designed to predict an individual’s long-term clinical outcome/prognosis, giving a basis for personalized treatment options. The Company’s MyPRS test provides a whole-genomic expression profile of a patient’s multiple myeloma (MM). The Company offers MyPRS test in its laboratory located in Little Rock, Arkansas. The Company is licensed to sell its test in all 50 states.
Cannabis Science Company Profile
Cannabis Science, Inc. is engaged in medical marijuana research and development. The Company works on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. The Company is involved in the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. The Company focuses on the development of governmentally approved pharmaceuticals, including CS-TATI1, CS-S/BCC-1 and neurological therapy under study or development. The Company’s subsidiaries include Cannabis Science BV and Cannabis Science International Holding BV.
Receive News & Ratings for Signal Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Signal Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.